Navigation Links
Essentialis Files Two New Patent Applications for Investigational Compound DCCR
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Essentialis, Inc. announced the February 27, 2012 filing of two new patent applications expanding the patent portfolio claiming its investigational triglyceride-lowering compound DCCR and new methods of using the drug.  The first is a continuation-in-part of a current application that includes data from the recently completed clinical trial, CT013; the second is a patent filing covering certain aspects of the use of DCCR in the treatment of very high triglycerides (VHTG).  The filing is the fourth patent application filed by Essentialis covering DCCR, and has the potential to extend patent protection on the product to 2033.  Essentialis already holds composition of matter protection for DCCR through 2028.

"With our portfolio of issued and pending patents, we already have very solid protection and these new applications will make our protection even stronger," said Aaron D. Berg, President and Chief Executive Officer, Essentialis, Inc. "We are targeting 2015 market availability for DCCR, and it is our hope to receive patent protection through 2033."

Essentialis already has two issued US patents (7,572,789 and 7,799,777) providing composition of matter protection to DCCR to 2028 and two granted European patents (EP1781265 and EP1968601) providing similar protection.  With the recent filings, Essentialis is prosecuting eight US patent applications.  The company is prosecuting these filings in all major pharmaceutical markets.  The current protection on the product includes claims to the active ingredient, pharmaceutical formulations, methods of manufacture, and a wide range of methods to treat multiple diseases.  In particular, the claims cover methods to treat dyslipidemia including co-formulation and co-administration with a range of drugs currently used in the treatment of patients with lipid disorders.  

About DCCR
DCCR is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation. It is in development for patients with very high triglyceride (TG) levels. Essentialis has completed an End-of-Phase 2 meeting with the FDA and has obtained an SPA covering a pivotal study. Essentialis expects to initiate Phase 3 clinical trials in 2012. DCCR is covered by multiple issued US and granted EU patents, which provide composition of matter protection until 2028. Essentialis has evaluated DCCR in several double-blind, placebo-controlled studies which demonstrated that the drug was well tolerated and that statistical significance for various endpoints was achieved in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide help support the acceptable safety of DCCR.

About Essentialis, Inc.
Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases. For more information visit http://essentialistherapeutics.com/

Contacts:

Kristie Kuhl
kkuhl@makovsky.com 
212.508.9642

Or

Aaron Berg 
aberg@essentialistherapeutics.com 
858-964-5022


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
2. Essentialis Promotes Aaron Berg to Chief Executive Officer
3. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
4. Essentialis to Submit SPA for Hypertriglyceridemia
5. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
6. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
7. Bionovo Files Registration Statement for Offering of Convertible Preferred Stock and Warrants
8. ReBuilder (RBRM) Files Complaints Against Stock Traders
9. Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
10. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
11. Department of Justice files consent decree of permanent injunction against Ranbaxy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):